Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Aptevo Therapeutics Q1 EPS $(9.95) Beats $(12.84) Estimate

Author: Benzinga Newsdesk | May 08, 2024 08:34am
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(9.95) per share which beat the analyst consensus estimate of $(12.84) by 22.51 percent. This is a 76.92 percent increase over losses of $(43.12) per share from the same period last year.

Posted In: APVO